Romuald Corbau
Chief Tech/Sci/R&D Officer chez ADVERUM BIOTECHNOLOGIES, INC.
Profil
Romuald Corbau is currently the Chief Scientific Officer at Adverum Biotechnologies, Inc. He previously held the same position at Freeline Therapeutics Holdings Plc from 2020 to 2021.
Additionally, he served as the Chief Scientific Officer at GenEdit, Inc. Dr. Corbau is a graduate of Université des Sciences et Technologies de Lille.
Postes actifs de Romuald Corbau
| Sociétés | Poste | Début |
|---|---|---|
| ADVERUM BIOTECHNOLOGIES, INC. | Chief Tech/Sci/R&D Officer | 29/01/2024 |
Anciens postes connus de Romuald Corbau
| Sociétés | Poste | Fin |
|---|---|---|
| FREELINE THERAPEUTICS HOLDINGS PLC | Chief Tech/Sci/R&D Officer | 20/08/2021 |
GenEdit, Inc.
 GenEdit, Inc. Pharmaceuticals: MajorHealth Technology GenEdit, Inc. develops gene therapies and gene editing-based therapeutics. Its proprietary nanoparticles applies for the development of CRISPR-based therapeutics and gene therapy products for a range of genetic diseases. The company was founded by Kunwoo Lee, Niren Murthy, and Hyo Min Park in 2016 and is headquartered in Berkeley, CA. | Chief Tech/Sci/R&D Officer | - |
Formation de Romuald Corbau
| Université des Sciences et Technologies de Lille | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| ADVERUM BIOTECHNOLOGIES, INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
GenEdit, Inc.
GenEdit, Inc. Pharmaceuticals: MajorHealth Technology GenEdit, Inc. develops gene therapies and gene editing-based therapeutics. Its proprietary nanoparticles applies for the development of CRISPR-based therapeutics and gene therapy products for a range of genetic diseases. The company was founded by Kunwoo Lee, Niren Murthy, and Hyo Min Park in 2016 and is headquartered in Berkeley, CA. | Health Technology |
Freeline Therapeutics Holdings Plc
 Freeline Therapeutics Holdings Plc BiotechnologyHealth Technology Freeline Therapeutics Holdings Plc engages in the business of developing and commercializing gene therapies. It also develops gene therapies for bleeding and other debilitating disorders. The company was founded by Markus Hörer and Amit Chunilal Nathwani in 2015 and is headquartered in Stevenage, the United Kingdom. | Health Technology |
